Dr. Christopher Flowers showcases a comprehensive and updated analysis of the ROSEWOOD study, evaluating the efficacy and safety of combining zanubrutinib with obinutuzumab versus obinutuzumab monotherapy.
Revisit Every OncLive On Air Episode From April 2024
Revisit the OncLive On Air Episodes From February 2024
Uproleselan Plus Chemotherapy Misses OS End Point in R/R AML
Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
Which JAK Inhibitor in Myelofibrosis: Deciding Factors in Treatment Selection
Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma
Vepdegestrant Plus Palbociclib Sustains Efficacy in Advanced ER+ Breast Cancer
Atezolizumab Plus Chemo Misses Mark in Early-Relapsing Unresectable TNBC
Olaparib/Durvalumab/Fulvestrant Combo Meets PFS End Point in HRR-Altered or MSI ER+/HER2– Breast Cancer
Frontline Atezolizumab Plus Sacituzumab Govitecan Elicits Responses in PD-L1+ Advanced TNBC